These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 21089112)

  • 1. Soluble receptors for advanced glycation end products (sRAGE) as a predictor of restenosis following percutaneous coronary intervention.
    McNair ED; Wells CR; Mabood Qureshi A; Basran R; Pearce C; Orvold J; Devilliers J; Prasad K
    Clin Cardiol; 2010 Nov; 33(11):678-85. PubMed ID: 21089112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low levels of soluble receptor for advanced glycation end products in non-ST elevation myocardial infarction patients.
    McNair ED; Wells CR; Qureshi AM; Basran RS; Pearce C; Orvold J; Devilliers J; Prasad K
    Int J Angiol; 2009; 18(4):187-92. PubMed ID: 22477551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of high sensitivity C-reactive protein by soluble receptor for advanced glycation end products.
    McNair ED; Wells CR; Mabood Qureshi A; Basran R; Pearce C; Orvold J; Devilliers J; Prasad K
    Mol Cell Biochem; 2010 Aug; 341(1-2):135-8. PubMed ID: 20339904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advanced Glycation End Products:Receptors for Advanced Glycation End Products Axis in Coronary Stent Restenosis: A Prospective Study.
    Pearce C; Islam N; Bryce R; McNair ED
    Int J Angiol; 2018 Dec; 27(4):213-222. PubMed ID: 30410293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The predictive value of inflammatory activity and markers of the adipo-insular axis on restenosis in patients with type 2 diabetes.
    Hage C; Grip L; Malmberg K; Rydén L; Wallander M; Saleh N
    Diab Vasc Dis Res; 2011 Apr; 8(2):143-9. PubMed ID: 21562066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble receptor for advanced glycation end products is associated with in-stent restenosis in patients with type 2 diabetes with drug-eluting coronary stents.
    Park HJ; Seo SM; Shin WS; Kim HY; Choi YS; Koh YS; Youn SG; Park MW; Chang K; Kim PJ; Jung HO; Baek SH; Chung WS; Seung KB; Yoo KD
    Coron Artery Dis; 2011 Jan; 22(1):12-7. PubMed ID: 21197704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are positively associated with circulating AGEs and soluble form of VCAM-1 in patients with type 2 diabetes.
    Nakamura K; Yamagishi S; Adachi H; Matsui T; Kurita-Nakamura Y; Takeuchi M; Inoue H; Imaizumi T
    Microvasc Res; 2008 May; 76(1):52-6. PubMed ID: 18474381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Do statins have a role in reduction/prevention of post-PCI restenosis?
    Prasad K
    Cardiovasc Ther; 2013 Feb; 31(1):12-26. PubMed ID: 21967674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ambulatory blood pressure variability is associated with restenosis after percutaneous coronary intervention in normotensive patients.
    Cay S; Cagirci G; Demir AD; Balbay Y; Erbay AR; Aydogdu S; Maden O
    Atherosclerosis; 2011 Dec; 219(2):951-7. PubMed ID: 22005197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Soluble TRAIL prevents RANTES-dependent restenosis after percutaneous coronary intervention in patients with coronary artery disease.
    Satoh D; Inami N; Shimazu T; Kajiura T; Yamada K; Iwasaka T; Nomura S
    J Thromb Thrombolysis; 2010 May; 29(4):471-6. PubMed ID: 19533303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel predictor of restenosis and adverse cardiac events: asymmetric dimethylarginine.
    Ari H; Ari S; Erdoğan E; Tiryakioğlu O; Ustündağ Y; Huysal K; Koca V; Bozat T
    Heart Vessels; 2010 Jan; 25(1):19-26. PubMed ID: 20091394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum levels of sRAGE, the soluble form of receptor for advanced glycation end products, are associated with inflammatory markers in patients with type 2 diabetes.
    Nakamura K; Yamagishi S; Adachi H; Kurita-Nakamura Y; Matsui T; Yoshida T; Imaizumi T
    Mol Med; 2007; 13(3-4):185-9. PubMed ID: 17592553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. B-type natriuretic peptide as a marker of asymptomatic re-stenosis after coronary implantation of a paclitaxel-eluting stent.
    Lo Mauro R; Arcoleo F; Lo Giudice A; Picone A; Schirosa M; Raspanti G; Cillari E; Enia F
    J Cardiovasc Med (Hagerstown); 2007 Dec; 8(12):1020-3. PubMed ID: 18163013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Receptor for advanced glycation end products polymorphisms in coronary artery ectasia.
    Aslan EI; Ozkara G; Kilicarslan O; Ser OS; Bostan C; Yildiz A; Diren Borekcioglu A; Ozturk O; Kucukhuseyin O; Yilmaz Aydogan H
    Gene; 2024 Jul; 916():148450. PubMed ID: 38588932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of stent length on restenosis in patients with acute myocardial infarction treated with primary percutaneous coronary intervention: analysis based on data from the Trial to Assess the Use of the Cypher Stent in Acute Myocardial Infarction Treated with Balloon Angioplasty (TYPHOON).
    Rozenman Y; Witzling V; Tamari I; Turkisher V; Kriviski M; Bode C; Henry P; Teiger E; Cebrian A; Stoll HP; Spaulding C
    EuroIntervention; 2009 Jun; 5(2):219-23. PubMed ID: 19527979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ratio of serum levels of AGEs to soluble form of RAGE is a predictor of endothelial function.
    Kajikawa M; Nakashima A; Fujimura N; Maruhashi T; Iwamoto Y; Iwamoto A; Matsumoto T; Oda N; Hidaka T; Kihara Y; Chayama K; Goto C; Aibara Y; Noma K; Takeuchi M; Matsui T; Yamagishi S; Higashi Y
    Diabetes Care; 2015 Jan; 38(1):119-25. PubMed ID: 25336748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced inflammatory response to coronary stenting marks the development of clinically relevant restenosis.
    Caixeta AM; Brito FS; Costa MA; Serrano CV; Petriz JL; Da Luz PL
    Catheter Cardiovasc Interv; 2007 Mar; 69(4):500-7. PubMed ID: 17285569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum levels of advanced glycation end-products (AGEs) and the decoy soluble receptor for AGEs (sRAGE) can identify non-alcoholic fatty liver disease in age-, sex- and BMI-matched normo-glycemic adults.
    Palma-Duran SA; Kontogianni MD; Vlassopoulos A; Zhao S; Margariti A; Georgoulis M; Papatheodoridis G; Combet E
    Metabolism; 2018 Jun; 83():120-127. PubMed ID: 29409822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma levels of soluble receptor for advanced glycation end products (sRAGE) and proinflammatory ligand for RAGE (EN-RAGE) are associated with carotid atherosclerosis in patients with peritoneal dialysis.
    Kim JK; Park S; Lee MJ; Song YR; Han SH; Kim SG; Kang SW; Choi KH; Kim HJ; Yoo TH
    Atherosclerosis; 2012 Jan; 220(1):208-14. PubMed ID: 21906738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inverse Association between Cardiac Troponin-I and Soluble Receptor for Advanced Glycation End Products in Patients with Non-ST-Segment Elevation Myocardial Infarction.
    McNair ED; Wells CR; Qureshi AM; Pearce C; Caspar-Bell G; Prasad K
    Int J Angiol; 2011 Mar; 20(1):49-54. PubMed ID: 22532771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.